Drug dis­cov­ery biotech look­ing in­to the ‘dark’ re­gions of the hu­man genome picks up a $40M+ Se­ries A

While the com­bo of ma­chine learn­ing and drug dis­cov­ery has man­aged to rake in a lot of cap­i­tal for com­pa­nies this year, one biotech is look­ing to the dark side of the genome to stand out.

Nu­cle­ome Ther­a­peu­tics, a UK-based com­pa­ny found­ed in 2019 and spun off from Ox­ford Uni­ver­si­ty, is seek­ing to cre­ate pre­ci­sion med­i­cines by de­cod­ing “dark mat­ter” from the hu­man genome to find tar­gets no one else has gone af­ter. The com­pa­ny has now gar­nered a £37.5 mil­lion ($42.4 mil­lion) Se­ries A to ad­vance its dis­ease pro­grams and build out its plat­form.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER